BioCentury
ARTICLE | Company News

FDA approves GSK's Incruse Ellipta for COPD

May 1, 2014 12:43 AM UTC

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said FDA approved an NDA for Incruse Ellipta umeclidinium bromide for the long-term, once-daily, maintenance treatment of airflow obstruction in adults with chr...